156 related articles for article (PubMed ID: 31818506)
1. Targeting Mutant KRAS for Immunogenic Cell Death Induction.
Galluzzi L
Trends Pharmacol Sci; 2020 Jan; 41(1):1-3. PubMed ID: 31818506
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
3. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
4. Targeting the KRAS G12C mutation in patients with advanced solid tumors.
Hong DS
Clin Adv Hematol Oncol; 2019 Nov; 17(11):612-614. PubMed ID: 31851163
[No Abstract] [Full Text] [Related]
5. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
6. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
He H; Xu C; Cheng Z; Qian X; Zheng L
Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
8. Dueling KRAS
Cancer Discov; 2020 Jan; 10(1):10. PubMed ID: 31822538
[TBL] [Abstract][Full Text] [Related]
9. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
[TBL] [Abstract][Full Text] [Related]
10.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
11. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.
Ricciuti B; Baglivo S; Ludovini V; Sidoni A; Metro G; Brambilla M; Siggillino A; Reda MS; Rebonato A; Maiettini D; Chiari R
Lung Cancer; 2018 Jun; 120():70-74. PubMed ID: 29748019
[TBL] [Abstract][Full Text] [Related]
14. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
15. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
16. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
17. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Biernacka A; Tsongalis PD; Peterson JD; de Abreu FB; Black CC; Gutmann EJ; Liu X; Tafe LJ; Amos CI; Tsongalis GJ
Cancer Genet; 2016 May; 209(5):195-8. PubMed ID: 27068338
[TBL] [Abstract][Full Text] [Related]
18. Overcoming
Luo J; Ostrem J; Pellini B; Imbody D; Stern Y; Solanki HS; Haura EB; Villaruz LC
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-11. PubMed ID: 35412860
[TBL] [Abstract][Full Text] [Related]
19. Cancer: Closing the door on KRAS-mutant lung cancer.
Cully M
Nat Rev Drug Discov; 2016 Nov; 15(11):747. PubMed ID: 27807355
[No Abstract] [Full Text] [Related]
20. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]